Ned Sharpless Joins Hatteras as Andrew Witty Returns as Chairman

Hatteras Ventures has added Ned Sharpless to its team, and Andrew Witty is returning to the venture capital firm as chairman, Endpoints News reports.

The two moves land at the same time and reshape the top of the firm's leadership structure. Sharpless, a name long associated with the upper reaches of American biomedical research and drug regulation, now sits on the investor side of the table at Hatteras, the North Carolina-based venture shop focused on life sciences. Witty, who previously worked with the firm before taking one of the most prominent jobs in global pharma, comes back in the chairman's seat.

For Hatteras, the appointments bring heavyweight operational and regulatory experience into a portfolio that lives or dies on the quality of its bets in biotech and medical innovation. Sharpless joins a firm that has built its reputation financing early-stage life science companies. Witty's return as chairman signals continuity with a figure the firm already knows well, rather than an outside hire.

Witty's path back to Hatteras runs through the top of the pharmaceutical industry. He led GlaxoSmithKline as CEO for years and later took the helm at UnitedHealth Group's Optum unit, one of the largest operations in American healthcare. His return to the venture firm where he had already served restores a familiar leader at the moment the firm is also bringing in Sharpless.

Sharpless arrives with a résumé that spans both academic medicine and federal drug regulation. He directed the National Cancer Institute and served as commissioner of the Food and Drug Administration, giving him a rare insider's view of how therapies move from laboratory hypothesis through clinical trials to approval. That background matters directly to the work Hatteras does: picking, funding and guiding young companies that must navigate the FDA if their products are ever to reach patients.

The pairing gives the firm two distinct but complementary kinds of authority. Witty carries global commercial scale — experience running organizations that market drugs and health services across dozens of countries. Sharpless carries scientific and regulatory depth from the institute that funds much of the nation's cancer research and the agency that decides which medicines reach the market. Together they cover the two ends of the value chain a biotech investor must understand.

The moves also say something about the direction of the talent flow in life sciences right now. Operators and regulators with decades inside large institutions increasingly land at venture firms, where their judgment on what works — scientifically, clinically, commercially — shapes which companies get founded and funded. Sharpless making that move to Hatteras fits the pattern of senior figures trading institutional leadership for portfolio influence.

Endpoints News first reported both appointments. Neither Hatteras, Sharpless nor Witty has publicly detailed the specific investment mandate, fund strategy changes or deal-flow responsibilities attached to the new roles, according to the report.

What comes next will show in the firm's deal sheet. Watch for Hatteras to deploy its reinforced bench — a former FDA commissioner evaluating science, a former GSK CEO chairing the board — in new company formations and financing rounds over the coming quarters.